gamifant®
emapalumab-lzsg

Summary of Relevant Codes for Gamifant® (emapalumab-lzsg)

Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Please see Important Safety Information on back cover and accompanying full Prescribing Information.

Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFNγ release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

gamifant®
emapalumab-lzsg

Summary of Relevant Codes

ICD-10-CM Diagnosis Code[1]

ICD-10-CM Code	Description
D76.1	Hemophagocytic lymphohistiocytosis

EAPG Code[2]

EAPG Code	Description
780	Other hematologic diagnoses

HCPCS Code for Product[3]

HCPCS Code	Description
J9210	Injection, emapalumab-lzsg, 1 mg

NDC Numbers[4]

NDC Numbers	Description
72171-501-01	One 10-mg/2-mL (5 mg/mL) single-dose vial
72171-505-01	One 50-mg/10-mL (5 mg/mL) single-dose vial

Concomitant Medication[5]

HCPCS Code	Description
J1100	Dexamethasone sodium phosphate, 1 mg

EAPG=Enhanced Ambulatory Patient Group; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=*International Classification of Diseases, Tenth Revision, Clinical Modification*; NDC=National Drug Code.

Please see additional Important Safety Information on back cover and accompanying full Prescribing Information.

gamifant®
emapalumab-lzsg

Summary of Relevant Codes *(continued)*

CPT Code Examples

Procedure Type	CPT Code	Indications for Testing
Administration	**96365**[6]	Therapeutic, prophylactic, and diagnostic injections and infusions
Monitoring or Treatment Observation Codes		
Platelet counts	**85049**[7]	Monitoring – Lab test
WBC and differential	**85004**[8] **85048**[8]	Monitoring – Lab test
Ferritin	**82728**[9]	Monitoring – Lab test
Coagulopathy (D-dimer or fibrinogen)	**85610**[10]	Monitoring – PT/INR lab test
	85730[11]	Monitoring – APTT lab test
	85379[12]	Monitoring – D-dimer lab test
	85384[13]	Monitoring – Fibrinogen lab test
Splenomegaly	**76700**[14]	Ultrasound abdomen
	74160[14]	Computerized tomography (CT) scan of the abdomen with contrast
	74150[14]	CT scan of the abdomen without contrast
Fever (WBC)	**85025**[15]	Complete blood count (CBC) with differential
	85027[16]	CBC without differential
Tuberculosis	**86580**[17]	Skin test for tuberculosis (PPD)
	86480[17]	Tuberculosis test, cell mediated immunity measurement of gamma interferon antigen response
Adenovirus	**87798**[18]	Adenovirus DNA, qualitative, real-time PCR
Epstein Barr Virus (EBV)	**86664**[19]	EBV immunoassay
Cytomegalovirus (CMV)	**87252**[20] **87254**[20]	CMV, conventional and rapid, culture

APTT=activated partial thromboplastin time; CPT=*Current Procedural Terminology*; PCR=polymerase chain reaction; PPD=purified protein derivative; PT/INR=prothrombin time/international normalized ratio; WBC=white blood cell count.

Important Safety Information *(continued)*

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

DRG/APR-DRG Codes

DRG Codes[21]	Description
814	Reticuloendothelial & immunity disorders W MCC
815	Reticuloendothelial & immunity disorders W CC
816	Reticuloendothelial & immunity disorders W/O CC/MCC

Medicaid APR-DRG Codes[22]	Description
660-1– 660-4	Major hematologic/immunologic diagnosis, except sickle cell crisis & coagulation
663-1– 663-4	Other anemias and disorders of blood and blood-forming organs

APR-DRG=All Patient Refined Diagnosis Related Groups; DRG=Diagnosis-Related Group; W MCC=with major complications; W CC=with complications; W/O CC/MCC=without complications/major complications.

Please see additional Important Safety Information on back cover and accompanying full Prescribing Information.

gamifant®
emapalumab-lzsg

References:

1. ICD-10 Code for hemophagocytic lymphohistiocytosis D76.1. AAPC Coder website. https://coder.aapc.com/icd-10-codes/D76. Accessed September 11, 2019.

2. 3M Health Information Systems. EAPG listing: effective October 1, 2018. https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/page_content/attachments/DC%20EAPG%20Relative%20Weights%20Eff%2010-1-18%20DCO18023.pdf. Published August 23, 2018. Accessed September 11, 2019.

3. Centers for Medicare and Medicaid Services. HCPCS Quarterly Update. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Downloads/Other-Codes-2019-July-Revised.zip. Accessed September 11, 2019.

4. Gamifant [prescribing information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; November 2018.

5. HCPCS Code J1100 Injection, dexamethasone sodium phosphate, 1 mg. AAPC Coder website. https://coder.aapc.com/hcpcs-codes/J1100. September 11, 2019.

6. CPT 96365, Under therapeutic, prophylactic, and diagnostic injections and infusions (excludes chemotherapy and other highly complex drug or highly complex biologic agent administration). AAPC Coder website. https://coder.aapc.com/cpt-codes/96365. Accessed September 11, 2019.

7. Platelet count. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=723&labCode=DLO. Accessed September 11, 2019.

8. White blood cell count (WBC) and differential. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=7064&searchString=85004. Accessed September 11, 2019.

9. Ferritin. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=457&searchString=82728. Accessed September 11, 2019.

10. Prothrombin time with INR. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=8847&searchString=85610. Accessed September 11, 2019.

11. von Willebrand comprehensive panel. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=19790&searchString=85730. Accessed September 11, 2019.

12. D-dimer, quantitative. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=8659&searchString=85379. Accessed September 11, 2019.

13. Fibrinogen QN. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=461&labCode=DLO. Accessed September 11, 2019.

14. Imaging Healthcare Specialists. *2018 CPT Code Reference Guide*. https://imaginghealthcare.com/wp-content/uploads/2018/03/IHS_4768_CPTGuide_Web.pdf. Accessed September 11, 2019.

15. CBC (includes differential and platelets). Quest Diagnostics website. https://testdirectory.questdiagnostics.com/test/test-detail/6399/cbc-includes-differential-and-platelets?p=r&q=CBC&cc=MASTER. Accessed September 11, 2019.

16. CBC (H/H, RBC, Indices, WBC, Plt). Quest Diagnostics website. https://testdirectory.questdiagnostics.com/test/test-detail/1759/cbc-hh-rbc-indices-wbc-plt?p=r&q=85027&cc=MASTER. September 11, 2019.

17. Tuberculin testing. HSMA Provider Resource Center website. https://hmsa.com/portal/provider/zav_pel.ph.TUB.500.htm. Accessed September 11, 2019.

18. Adenovirus DNA, qualitative, real-time PCR. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=16046&searchString=adenovirus. Accessed September 11, 2019.

29. Epstein-Barr virus antibody panel. Quest Diagnostics website. https://testdirectory.questdiagnostics.com/test/test-detail/6421/epstein-barr-virus-antibody-panel?p=r&q=Epstein-Barr%20Virus%20Antibody%20Panel&cc=MASTER. Accessed September 11, 2019.

20. Cytomegalovirus, conventional and rapid, culture. Quest Diagnostics website. https://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=2627&searchString=CMV%20culture. Accessed September 11, 2019.

21. Diseases and disorders of blood, blood-forming organs and immunological disorders DRG Code Range 799-816. AAPC Coder website. https://coder.aapc.com/drg-codes-range/17. Accessed September 11, 2019.

22. Montana Department of Health and Human Services. APR-DRG Table of Weights and Thresholds and Inpatient Pricing Calculator; 3M™ APR DRG Grouper V29.0. https://medicaidprovider.mt.gov/Portals/68/docs/aprdrg/aprdgfs/aprdrgfs04012012.pdf. Accessed September 11, 2019.

Please see Important Safety Information on back cover and accompanying full Prescribing Information.

gamifant®
emapalumab-lzsg

Indication and Usage

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Important Safety Information

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have positive purified protein derivative (PPD) test result or positive IFNγ release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions (≥10%) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastro-intestinal hemorrhage, epistaxis, and peripheral edema.

Please see the full Prescribing Information for Gamifant.

sobi